期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

雄激素受体对乳腺癌细胞增殖及相关分子表达作用的研究进展 被引量：4

The role of androgen receptor in proliferation and relative molecules expression of breast cancer cell
下载PDF
导出
摘要 乳腺癌是激素依赖性肿瘤。除雌激素外,雄激素在乳腺癌的发生发展中也发挥重要作用。雄激素受体(AR)经雄激素作用激活,通过不同方式调控雌激素受体(ER)及芳香化酶的表达,影响人表皮生长因子受体-2(HER-2)、孕激素受体(PR)、E-钙黏蛋白的转录,对乳腺癌细胞的增殖既有抑制也有促进作用。AR还与雌激素受体调节剂(SERMs)他莫昔芬及芳香化酶抑制剂(AIs)的耐药机制有关。深入研究AR调控乳腺癌分子表达的机制有助于将AR作为治疗靶点,提高乳腺癌内分泌治疗的疗效。 Breast cancer is known as a hormone-responsive cancer. Apart from estrogen,androgen also plays a critical role in the occurrence and development of breast cancer. The binding of androgen to androgen receptor（ AR） leads to the activation of AR,which interacts with molecules in the nuclear,resulting in up-regulation or down-regulation of target proteins. AR is associated with the expression of ERs,aromatase,human epidermal growth factor receptor-2（ HER-2）,progesterone receptor（ PR） and E-cadherin. The resistant mechanisms of aromatase inhibitions（ AIs） and selective estrogen receptor modulators（ SERMs） Tamoxifen are also relevant with AR. Further investigation of AR signaling makes it possible to be an effective therapeutic target for breast cancer.
作者 朱蔼瑜 管晓翔
机构地区 南京南方医科大学南京临床医学院 南京军区南京总医院肿瘤内科
出处 《临床肿瘤学杂志》 CAS 2014年第12期1143-1146,共4页 Chinese Clinical Oncology
基金 国家自然科学基金资助项目(81272252) 江苏省自然科学基金资助项目(BK2011656)
关键词 乳腺癌 雄激素受体 雌激素受体 芳香化酶 人表皮生长因子受体-2 Breast cancer Androgen receptor（AR） Estrogen receptor（ER） Aromatase Epidermal growth factor receptor 2（HER-2）
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献34

  • 1Hall RE, Aspinall JO, Horsfall D J, et al. Expression of the an- drogen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer [J]. Br J Cancer, 1996, 74(8) :1175-1180.
  • 2Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer [ J ]. Neoplasia, 2008, 10 ( 6 ) : 542-548.
  • 3Lanzino M, Marls P, Sirianni R, et al. DAX-1, as an androgen- target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation [ J/ OL ]. Cell Death Dis, 2013 [ 2014-02-20 ].http ://www.ncbi.nlm. nih. gov/pubmed/23846226.
  • 4Loibl S, MUller BM, von Minckwitz G, et al. Androgen receptor expression in primary breast cancer and its predictive and prognos- tic value in patients treated with neoadjuvant chemotherapy [J]. Breast Cancer Res Treat, 2011, 130(2) : 477-487.
  • 5Castellano I, Allia E, Accortanzo V, et al. Androgen receptor ex- pression is a significant prognostic factor in estrogen receptor posi- tive breast cancers [J].Breast Cancer Res Treat, 2010, 124 ( 3 ) : 607-17.
  • 6Gasparini P, Fassan M, Cascione L, et al.Androgen receptor sta- tus is a prognostic marker in non-basal triple negative breast canc- ers and determines novel therapeutic options [ J/OL ]. PLoS One, 2014[ 2014-02-20].http ://www.nebi.nlm.nih.gov/pubmed/245- 05496.
  • 7Eiek GN, Thornton JW. Evolution of steroid receptors from an es- trogen-sensitive ancestral receptor [ J ]. Mol Cell Endocrinol,2011, 334(1-2):31-38.
  • 8Enmark E, Peho-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and ex- pression pattern[J]. J Clin Endocrinol Metab, 1997, 82( 12): 4258-4265.
  • 9Lavery DN, Bevan CL. Androgen receptor signalling in prostate cancer : the functional consequences of acetylation [ J/OL ]. J Bi- omed Biotechnol, 2011 [ 2014-02-20]. http ://www. ncbi. nlm. nih. gov/pmc/articles/PMC3022265/.
  • 10Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer[J]. Cancer Res, 2009, 69(15) :6131-6140.

同被引文献69

  • 1孔丽凤,赵峰,李景英,房新志.ERβ、C-erbB-2在乳腺癌组织中的表达及其与内分泌治疗效果的关系[J].新疆医科大学学报,2008,31(12):1667-1670. 被引量：3
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J]. CA Cancer J Clin, 2012, 62(1) : 10-29.
  • 3Moreno-Aspitia A, Perez EA. Anthracycline-and/or taxane-re- sistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends [ J ]. Clin T- her, 2009, 31(8): 1619-1640.
  • 4Qi XF, Zheng L, Lee KJ, et al. HMG-CoA reductase inhibitors induce apoptosis of lymphoma ceils by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of meva- lonate pathway [J]. Cell Death Dis, 2013, 4: e518.
  • 5Spampanato C, Sarnataro M, Giordano E, et al. Simvastatin in- hibits cancer cell growth by inducing apoptosis correlated to acti- vation of Bax and down-regulation of BCL-2 gene expression [ J]. Int J Oncol, 2012, 40(4) :935-941.
  • 6Kochuparambil ST, A1-Husein B, Goc A, et al. Anticancer effi- cacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression [J]. J Pharmacol Exp Ther, 2011, 336(2) : 496-505.
  • 7Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents [ J ]. Chn Cancer Res, 2012, 18(13) :3524-3531.
  • 8Buchwald H. Cholesterol inhibition, cancer and chemotherapy [J]. Lancet, 1992, 339(8802) :1154-1156.
  • 9Sassano A, Katsoulidis E, Antico G, et al. Suppressive effects of statins on acute promyeloeytic leukemia cells [ J ]. Cancer Res, 2007, 67(9) : 4524-4532.
  • 10Liang YW, Chang CC, Hung CM, et al. Preclinical activity of simvastatin induces cell cycle arrest in G1 via blockade of eyclin D-Cdk4 expression in non-small cell lung cancer(NSCLC) [ J]. Int J Mol Sci, 2013, 14(3) :5806-5816.

引证文献4

二级引证文献20

临床肿瘤学杂志
2014年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部